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Gammaglobulin for primary immuno-
deficiency: when should it be used?
Gamaglobulina para imunodeficiência primária: quando usar?
Pérsio Roxo-Junior1
ABSTRACT
Antibodies are an essential component of the adaptative immune response and hold long-term memory
of the immunological experiences throughout life. Antibody defects represent approximately half of the
well-known primary immunodeficiencies requiring gammaglobulin replacement therapy.
On the other hand this therapy can be used for some diseases that do not belong to this group, like hyper
IgM syndrome, immunodeficiency with thymoma and severe combined immunodeficiency. This therapy
is a safe procedure and induces dramatic improvement in the clinical outcome of patients, reducing the
risks of death and complications.
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Primary immunodeficiencies (PID) are a het-
erogeneous group of diseases caused by genetic de-
fects involving one or more sectors of the immuno-
logic response.1,2 Since the first report of congenital
agammaglobulinemia3 in 1952, approximately 180 dif-
ferent types of PID have been described.
PID are classified and divided into 8 groups
according to the immunologic system primarily involved
(Table 1).4
PID are considered to be diseases of low preva-
lence, affecting approximately 1 individual in 2,000
liveborns, especially in populations with a high rate of
consanguinity.5 Deficiencies predominantly involving
antibodies are the most frequent, corresponding to about
half the cases.6
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Table 1: Classification of PID.
1. Deficiencies predominantly of antibodies
2. Combined deficiencies (T and B cells)
3. Other well-defined immunodeficiencies
4. Diseases of immunologic deregulation
5. Congenital phagocyte defects
6. Innate immunity defects
7. Auto-inflammatory diseases
8. Deficiencies of the complement system
Adapted from Chapel, 20124.
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The most typical manifestations of PID are re-
current or prolonged infections caused by specific
microorganisms or by germs of low virulence, weight
and height growth retardation, an inadequate response
to habitually used antibiotic therapy, high risks of com-
plications and hospitalizations and severe reactions to
attenuated vaccines.2
The evaluation of immunologic competence is
essential for the diagnostic definition of PID. The rec-
ommendation is that laboratory investigation be started
with low-cost and easy to perform screening tests
based on clinical history and physical examination. The
main screening tests for the investigation of PID
adopted by the Service of Pediatric Allergy and Im-
munology of the School of Medicine of Ribeirão Preto
- University of São Paulo2 are listed in Table 2.
Table 2: Exams for PID screening.
1. Complete blood count
2. Determination of serum immunoglobulins (IgG, IgM, IgA
and IgE)
3. Cavum and chest X-rays
4. Delayed hypersensitivity skin tests
5. NBT reduction test
6. Total hemolytic complement (CH50)
7. HIV serology
Adapted from Roxo-Jr, 20092.
Treatment should be instituted as soon as the
diagnosis is confirmed in order to prevent possible
complications and to improve quality of life and prog-
nosis. Rigorous measures of environmental and per-
sonal hygiene are recommended, as well as education
of patients and relatives about the disease, nutritional
support; a diet free of raw or poorly cooked foods;
frequent nasal washes with physiological saline; drain-
ing of secretions by means of respiratory physi-
otherapy; avoiding vaccines consisting of attenuated
agents in some PID, especially severe cell immunity
deficiencies and agammaglobulinemias; infusion of
previously irradiated blood derivatives in order to pre-
vent graft-versus-host reactions; aggressive and early
treatment of infections with antimicrobial agents based,
whenever possible, on previous pathogen isolation by
culture of organic fluids and on the antibiogram, and
treatment of comorbidities and their complications.
Gammaglobulin Replacement
Therapy
Standard human gammaglobulins were first
developed in the 1950s, while the introduction of intra-
venous (IVIG) and subcutaneous (SCIG) preparations
in the 1980s.
The first immunological description of PID was
made by Ogden Bruton in 1952 in a patient who pre-
sented with recurrent infections and several episodes
of sepsis. The disease was termed agammaglobuli-
naemia, as it was identified by the absence of the
gamma fraction after immunoelectrophoresis of se-
rum from the patient. Eventually, he was treated with
human gammaglobulin and this intervention led to a
decrease in the frequency of infections.3
Gammaglobulins are now employed to treat a
wide range of other conditions that are associated with
hypogammaglobulinaemia, including graft versus host
disease, multiple myeloma, and chronic lymphoid leu-
kaemia, as well as diseases in which their ‘‘immu-
nomodulatory’’ properties have a major impact such
as idiopathic thrombocytopenia purpura, Kawasaki
disease, Guillain-Barré syndrome, and polymyositis/
dermatomyositis.7
Gammaglobulin replacement therapy (GRT) is
the main therapeutic tool for deficiencies pedominantly
involving antibodies. However, its use should take into
account several aspects related to efficacy and safety.8
Preparations mainly contain IgG at sufficient concen-
trations to protect against sepsis and to reduce recur-
rent or chronic pulmonary infections, reflecting the
immunologic memory of the donors.9
GRT has proved to be highly effective by sig-
nificantly reducing the incidence of acute respiratory
infections, especially pneumonias, and reducing the risk
for chronic lung disease. In addition, this procedure
reduces the frequency of hospitalizations due to in-
fection, with a consequent reduction of mortality and
improving quality of life.8
The decision to offer GRT should be based on:
the patient’s diagnosis; proper assessment of serum im-
munoglobulin levels; other immunological parameters10;
and on secondary causes of hypogammaglobulinaemia.
The absolute indications for the use of GRT in
PID are defects of immunoglobulin production10 and
are represented in Table 3.
Several conditions represent relative indica-
tions for the use of GRT, depending on their sever-
ity and number of infections10,11 and are represented
in Table 4.
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normal immunoglobulin levels associated with severe
asthma frequently show significant clinical improve-
ment of asthma after GRT. This improvement may
have been probably due to the significant reduction of
respiratory infections, which play an important role in
triggering exacerbation and intensification of the bron-
chial inflammatory process in these patients.2
The dose and the frequency of application should
be tailored to each patient based on his clinical re-
sponse and on the determination of serum IgG levels,
which ideally should be above 500 mg/dL after 4 weeks
of infusion. In the presence of acute infections the
catabolism of gammaglobulin is usually increased and
extra infusions may be necessary.
In general the recommended dose of IVIG for
patients with PID is 400 to 600 mg/kg, but it may vary
depending on the severity of the infections and hypog-
ammaglobulinaemia. The infusions shoud be every
three to four weeks to maintain IgG levels adequate
to prevent severe infections.11
The initial therapeutic scheme of SCIG is 100
mg/kg every seven days or 200 mg/kg every 14 days.
This procedure permits reaching IgG concentrations
similar to those obtained with IVIG. Thus SCIG is as
effective as IVIG for patients with PID, also having
other advantages such as not requiring venous access
and the possibility of home treatment.12
The most common side effects of IVIG are
fever, nausea, vomiting, and myalgia, especially dur-
ing or some hours after the first infusions. These re-
actions are frequently related to the rate of infusion or
to the presence of a concomitant infection.13 Some
reactions like urticaria, angioedema, bronchospasm and
anaphylaxis may occur due to the presence of IgG
aggregates or anti-IgA antibodies, however fortunately
they are uncommon. On the other hand, high IVIG
doses administered for immunomodulating purposes
can cause some rare manifestations like hemolysis with
a positive Coombs test; aseptic meningitis; thromboem-
bolism; or increases in serum creatinine levels. Moreo-
ver there are rare reports of transmission of hepatitis
B and C virus.14
SCIG has a lower frequency of adverse reac-
tions than IVIG. Thus SCIG is indicated for patients
with severe adverse reactions to IVIG and for pa-
tients with difficult venous access. The more frequent
side effects of SCIG are local like edema, erythema
and pain at the site of infusion, especially during the
first weeks of treatment.15
Table 4: Relative indications for GRT in PID.
Subclass deficiency if associated with specific antibody
defect
Specific antibody defect with normal immunoglobulin
levels
IgA deficiency if associated with subclass deficiency or
with specific antibody defect
Transient hypogammaglobulinemia of infancy
Hyper IgE syndrome if associated with specific antibody
defect
Ataxia-telangiectasia if associated with hypogammaglob-
ulinemia or specific antibody defect
Wiskott-Aldrich syndrome
WHIM syndrome (warts, hypogammaglobulinemia, in-
fections and myelokathesis)
DiGeorge syndrome if associated with hypogammaglob-
ulinemia or specific antibody defect
Adapted from Stiehm et al, 201010 and from Condino-Neto et al,
201311.





NEMO deficiency with hypogammaglobulinemia
Adapted from Stiehm et al, 201010.
Some considerations are relevant. Children with
a diagnosis of transient hypogammaglobulinemia just
require GRT when they present severe respiratory
infections. Patients with IgA deficiency just benefit
from treatment with gammaglobulin if associated with
deficiency of IgG subclasses or associated with de-
fects in the production of antipolysaccharide antibod-
ies with normal immunoglobulin levels. However cau-
tion is needed regarding possible anaphylactic reac-
tions, especially among patients with the presence of
circulating anti-IgA antibodies. In these cases, the
option should be for IgA-free gammaglobulin prepa-
rations or preparations containing very low IgA con-
centrations.11
Patients with hypogammaglobulinemia or with
specific deficiency of polysaccharide antibodies with
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Monitoring of patients
Some laboratory tests are recommended before
the initiation of GRT to provide a comprehensive as-
sessment of the patient’s health condition8. Such evalu-
ation should include:
• Complete haemoleukogram;
• Serum levels of all immunoglobulins (IgG, IgA, IgM,
and IgE);
• Titres of antibodies specific to protein and polysac-
charide antigens from vaccines (may not be neces-
sary except in cases of specific antibody deficien-
cies, since levels <200 mg/dL might give false nega-
tive titres);
• Lymphocyte populations in peripheral blood (B, T,
and NK lymphocytes);
• Evaluation of the lungs including pulmonary func-
tion testing and high-resolution contrasted computed
tomography;
• Assessment of hepatic and renal function (total and
direct bilirubin, transaminases, gamma glutamyl
transferase, lactate dehydrogenase, blood urea ni-
trogen, and serum creatinine);
• Assessment of blood-acquired diseases such as
HIV, hepatitis B, hepatitis C, toxoplasmosis, cytome-
galovirus infection, mononucleosis, rubella, Chagas
disease, malaria, leishmaniasis, herpes simplex vi-
rus infection, or other infectious diseases according
to the geographical particularities.
With aim of verify the occurrence of adverse
reactions, patients should be submitted to rigorous clini-
cal and laboratory monitoring, as follows11:
• Determining vital signs before the beginning of in-
fusion, at each change in rate and 30 minutes after
the end of infusion;
• Determining the vital signs immediately if there is a
report of any adverse reaction at any time during
infusion and 5 minutes after the solution of the prob-
lem;
• Performing laboratory tests every 6 months: blood
count, erythrocyte sedimentation rate, C-reactive
protein and polymerase chain reaction (used to de-
tect sub-clinical infections); measurement of immu-
noglobulin levels (IgG, IgM and IgA); renal and he-
patic function.
Final considerations
The main therapeutic tool for patients with hy-
pogammaglobulinemia is GRT by the intravenous or
subcutaneous route. The benefits of this treatment are
well established. Patients present reduction of number
of infections as well as the severity and number of
hospitalizations. The primary consequence is a better
prognosis and lower mortality.
RESUMO
Anticorpos são componentes essenciais da resposta imunológica adaptativa e apresentam memória
imunológica em longo prazo. Defeitos de anticorpos representam aproximadamente metade das
imunodeficiências primárias conhecidas e requerem terapia de reposição de gamaglobulina.
Por outro lado, esta modalidade terapêutica pode ser usada para algumas outras doenças que não
pertencem a este grupo, como síndrome de hiper IgM, imunodeficiência com timoma e imunodeficiên-
cia combinada grave. Este tratamento é um procedimento seguro e acarreta em significativa melhora
clínica dos paceintes, reduzindo os riscos de morte e complicações.
Palavras-chave: Imunidade. Síndromes de Deficiência Imunológica. Infecção. Imunoglobulinas. Tera-
pia Biológica.
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